Conagra Brands Inc vs Neurocrine Biosciences Inc — how do they compare? Conagra Brands Inc trades at $14.93 (market cap $7.07B), while Neurocrine Biosciences Inc trades at $161.94 (market cap $16.76B). The key difference: Neurocrine Biosciences Inc is far larger — about 2.4× Conagra Brands Inc's market cap, and Conagra Brands Inc pays a 8.29% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| CAG | NBIX | |
|---|---|---|
Market Cap | $7.07B | $16.76B |
Sector | Consumer Staples | Health |
52-Week High | $20.02 | $185.50 |
52-Week Low | $12.58 | $123.10 |
Enterprise Value | $14.12B | $16.78B |
Dividend Yield | 8.29% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Trailing returns across standard periods
Latest headlines on both assets
Conagra Brands is a packaged food company that operates predominantly in the United States (over 90% of revenue and profits). It has a significant presence in the freezer aisle, with brands such as Marie Callender's, Healthy Choice, Banquet, and Birds Eye. Other popular brands include Duncan Hines, Hunt's, Slim Jim, Vlasic, Orville Redenbacher's, Reddi-wip, Wish-Bone, and Chef Boyardee. While the majority of revenue is sold into the U.S. retail channel, 9% of fiscal 2022 sales were to the food-service channel, down from 11% in fiscal 2019 due to the pandemic.
Read more on CAG →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →